Efficacy and Safety of Dabigatran in the Treatment and Secondary Prevention of Venous Thromboembolism in Children with Central Line or Implantable Device–related Thrombosis Efficacy and Safety of Dabigatran in the Treatment and Secondary Prevention of Venous Thromboembolism in Children with Central Line or Implantable Device–related Thrombosis

Efficacy and Safety of Dabigatran in the Treatment and Secondary Prevention of Venous Thromboembolism in Children with Central Line or Implantable Device–related Thrombosis

On Wednesday, July 21, 2021, Manuela Albisetti, Head of the Hemophilia Center of the University Children’s Hospital in Zurich, Switzerland, presented results from research that looked at the efficacy and safety of dabigatran in treatment and secondary prevention of venous thromboembolism (VTE) in children with central venous catheter (CVC)- or implantable device (ID)-related thrombosis.

Read more
The VWF-A1 Domain Binding Aptamer BT200 Prolongs the Half-Lives of Different Factor VIII (FVIII) Products in Patients With Severe Hemophilia A and Increases FVIII Levels in Non-Severe Hemophilia A The VWF-A1 Domain Binding Aptamer BT200 Prolongs the Half-Lives of Different Factor VIII (FVIII) Products in Patients With Severe Hemophilia A and Increases FVIII Levels in Non-Severe Hemophilia A

The VWF-A1 Domain Binding Aptamer BT200 Prolongs the Half-Lives of Different Factor VIII (FVIII) Products in Patients With Severe Hemophilia A and Increases FVIII Levels in Non-Severe Hemophilia A

Cihan Ay, M.D., of the Medical University of Vienna in Vienna, Austria, presented findings from the late-breaking results of the PEGylated aptamer, BT200, in hemophilia A patients.
Read more
Prevention of Thrombocytopenia and Thrombosis in Heparin-Induced Thrombocytopenia (HIT) Using Deglycosylated KKO: A Novel Therapeutic for HIT? Prevention of Thrombocytopenia and Thrombosis in Heparin-Induced Thrombocytopenia (HIT) Using Deglycosylated KKO: A Novel Therapeutic for HIT?

Prevention of Thrombocytopenia and Thrombosis in Heparin-Induced Thrombocytopenia (HIT) Using Deglycosylated KKO: A Novel Therapeutic for HIT?

On Tuesday, July 20, 2021, Amrita Sarkar, Ph.D., of the University of Pennsylvania and Children's Hospital of Philadelphia in Philadelphia presented research about heparin-induced thrombocytopenia (HIT) and a potential new therapeutic.
Read more
RSS
12345678